Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

transcreation

- PMLiVE

NHS leaders urge government to take action on energy costs or risk ‘public health emergency’

There are concerns that widespread fuel poverty will increase the already high number of annual deaths associated with cold homes – estimated at around 10,000 a year

- PMLiVE

COVID-19 linked to higher risk of brain fog, dementia and psychosis in new study

The study also found that adults faced an increased risk of anxiety and depression, but this subsided within two months of illness

- PMLiVE

GSK awarded first-ever UNICEF contract for malaria vaccine in deal worth £170m

In 2020, nearly half a million children died from malaria in Africa alone, a rate of one child death per minute

- PMLiVE

CureVac announces start of phase 1 trial of modified COVID-19 mRNA vaccine candidate

Developed in collaboration with GSK, CV0501 is specifically designed to protect against the Omicron variant

- PMLiVE

Medscape Education Invites Clinicians to Connect to the Conversation With New Mental Health and Wellness Learning Center

Medscape Education, the leading destination for continuous professional development for healthcare professionals, has launched Building Bridges Between Mental Health and Wellness, a learning center focusing on mental health and wellness for both patients...

Medscape Education

There’s No Going Back: How COVID-19 will Change Pharma Forever

Munther Baara, VP Product Strategy and Innovation at EDETEK, discusses all things clinical trials. Especially, we discuss the current gaps and the impact of COVID-19 on the way Pharma approaches...

Impetus Digital

- PMLiVE

Shaping the dermatology landscape: Independent expert analysis of the pipeline in 5 disease areas

Leading dermatologists discuss the innovations shaping 5 chronic skin diseases—psoriasis, atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa—and share the challenges and opportunities for biopharmaceutical companies developing innovative treatments.

Avalere Health

- PMLiVE

Transforming clinical trials to accelerate drug development

There are great opportunities for the UK to take the learnings from the pandemic and build on our competitive advantages to strengthen and grow our clinical research environment. The aim...

- PMLiVE

How the WHO hepatitis strategy measures up in the field

With hepatitis cases on the rise, Dr Anthony Martinez, member of the International Hepatitis Education Program (IHEP), shares his perspective on the World Health Organization’s new strategy for hepatitis elimination...

Avalere Health

- PMLiVE

Merck and Orna agree on deal worth $3.5bn for RNA technology

The companies will work together to develop proprietary circular RNA technology

- PMLiVE

AstraZeneca and Merck’s Lynparza combination therapy receives FDA priority review in first-line prostate cancer

Prostate cancer is the second most common cancer in male patients in the US, projected to cause around 35,000 deaths in 2022

- PMLiVE

bluebird bio’s beta-thalassaemia gene therapy receives FDA approval

Patients with the most severe form of the blood disorder develop life-threatening anaemia and have to receive regular blood transfusions

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links